Skip to main content

Recombinant Cytomegalovirus Cytomegalovirus gH Pentamer Complex VR1814 His (C-Term) Protein

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14809

Novus Biologicals, part of Bio-Techne
Discontinued Product
NBP3-14809 has been discontinued. View all Cytomegalovirus gH Pentamer Complex products.

Key Product Details

Source

HEK293

Tag

His (C-Term)

Conjugate

Unconjugated

Applications

SDS-PAGE

Product Specifications

Description

Recombinant human cytomegalovirus pentamer protein complex (NCBI Accession#: ACZ79986), consisting of proteins UL75 (gH), UL115 (gL), UL128, UL130 and UL131A, contains a His-tag.

Concentration: 1.0-1.5mg/ml

Purity

>95% pure by SDS-PAGE

Application Notes

Purified protein binds NRP-2 receptor in ELISA.

Specificity

Cytomegalovirus gH Pentamer Complex comprises five viral proteins (gH, gL, UL128, UL130, and UL131A). This complex has been shown to bind our recombinant NRP-2 protein in ELISA.

Protein / Peptide Type

Recombinant Protein

Scientific Data Images

SDS-PAGE: Recombinant Cytomegalovirus Cytomegalovirus gH Pentamer Complex VR1814 His (C-Term) Protein [NBP3-14809]

SDS-PAGE: Recombinant Cytomegalovirus Cytomegalovirus gH Pentamer Complex VR1814 His (C-Term) Protein [NBP3-14809]

SDS-Page: Cytomegalovirus gH Pentamer Complex Recombinant Protein Antigen [NBP3-14809] - Coomassie-stained SDS-PAGE showing Cytomegalovirus gH Pentamer Complex.

Formulation, Preparation and Storage

NBP3-14809
Formulation Dulbecco's PBS, 0.2 um filter sterilised.
Preservative No Preservative
Concentration Please see the vial label for concentration. If unlisted please contact technical services.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store at -80C. Avoid freeze-thaw cycles.

Background: Cytomegalovirus gH Pentamer Complex

Human cytomegalovirus, also called HCMV or human herpesvirus 5, is a double-stranded DNA, enveloped virus of 230-250 kilobases (kb) that is a member of the Herpesviridae family and the subfamily Betaherpesvirinae (1,2). Other herpesviruses, which share the characteristic of lifelong latency following primary infection, include herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), varicella zoster virus (VSV), and Epstein-Barr virus (EBV) (1). Cytomegalovirus entry into cells is mediated by a trimeric complex of glycoproteins gH, gL, and gO and a pentamer made of proteins gH, gL, UL128, UL130, and UL131A (1,3). The trimer binds PDGFRalpha for entry into fibroblasts while the pentamer binds neuropilin-2 for entry into endothelial and epithelial cells (1,4). Additionally, the fusion protein glycoprotein B (gB) plays a pivotal role for cytomegalovirus entry into the host cell membrane (1,3).

Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).

References

1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w

2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z

3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078

4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437

5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493

Alternate Names

envelope glycoprotein H

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...